CD274 and esophageal cancer: Pembrolizumab prolonged OS vs chemotherapy as second‐line therapy for advanced esophageal cancer in patients with PD‐L1 CPS ≥ 10, with fewer treatment‐related adverse events (KEYNOTE‐181).